BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III (World)
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Progress With RHB-104 Ongoing Phase 3 Program For Crohn's Disease Following FDA Meeting 1/29/2015
OSE Pharma Collaboration For Cancer Trial 1/29/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Celgene (CELG) Receives Positive CHMP Opinion For OTEZLA (apremilast), The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Amgen (AMGN) And AstraZeneca PLC (AZN) Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 11/12/2014
FDA Grants QIDP Fast-Track Designation To RedHill Biopharma Ltd. (RDHL)'s Phase 3 H. Pylori Drug RHB-105 11/10/2014
Genmab A/S (GEN.CO) Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL 11/6/2014
Nine Out Of 10 Lost Weight With Novo Nordisk A/S (NVO)'s Obesity Drug Liraglutide 11/5/2014
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014
Sanofi Pasteur (SASY.PA)'s Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial 11/4/2014
Novo Nordisk A/S (NVO) Release: New Phase 3a Data Demonstrate That 9 Out Of 10 Adults With Obesity Lost Weight With Liraglutide 3 Mg And Clinical Trial Completers Lost An Average Of 9.2% 11/4/2014
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) To Be PBS Listed For Metastatic Pancreatic Cancer 10/31/2014
CSL Behring Release: Evidence Presented At The 16th Biennial Meeting Of The European Society For Immunodeficiencies (ESID) Supports Individualized Dosing With Hizentra® 10/31/2014
Helsinn Group Release: New Data On Fatigue From ROMANA 1, A Pivotal Phase III Study Of Anamorelin In Advanced NSCLC Patients With Cachexia Presented At 2014 Chicago Multidisciplinary Symposium In Thoracic Oncology 10/30/2014
Novartis AG (NVS) Expects New Heart Failure Drug As "Multi-Blockbuster" 10/29/2014
Lipid Therapeutics' European Partner Dr. Falk Pharma Gmbh Enrolls First Patients Into Pivotal Phase 3 Trial With LT-02, A Novel Therapy For Ulcerative Colitis (UC) 10/29/2014
Alchemia (ACL.AX) Shares Plummet On Failed Colorectal Cancer Trial 10/27/2014
Roche (RHHBY) Release: CHMP Recommends Label Update For Esbriet In Idiopathic Pulmonary Fibrosis, Strengthening Mortality Benefit And Reinforcing Safety Profile 10/24/2014
Novartis AG (NVS)'s AIN457 Meets Primary Endpoint In Two Late Stage Studies 10/23/2014
MorphoSys AG To Receive Milestone Payment For Guselkumab Phase 3 Program 10/23/2014
Immune Pharmaceuticals, Inc. Release: New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease 10/22/2014
Regeneron (REGN), Sanofi (SAN.PA) Begin Pivotal Phase 3 Study For Eczema Drug Dupilumab 10/20/2014
Basilea Pharmaceutica (BSLN.SW) Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 10/16/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Novartis AG (NVS)'s Secukinumab Has Consistent Activity In Psoriasis 10/14/2014
AbbVie (ABBV) Announces Late-Breaking Results From Phase 3 Trial Of HUMIRA® (Adalimumab) In Hidradenitis Suppurativa (HS) Patients At The European Academy Of Dermatology And Venereology Congress 10/13/2014
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014
Cardio3 BioSciences Receives Authorization To Enroll Patients In Switzerland In Its Phase 3 Clinical Trial Chart-1 10/13/2014
Smith & Nephew plc (SNN)’s “Spray-On-Skin” For Leg Ulcers Flops In Trial 10/13/2014
Bioniche Life Sciences Inc. (BNC) To Publish Comprehensive Phase 3 Clinical Trial Results In The Journal Of Urology 10/10/2014
Alchemia Announces Database Lock Of Its HA-Irinotecan Pivotal Phase 3 Trial In Metastatic Colorectal Cancer 10/10/2014
InSightec To Share Key Insights And Progress At The 4th Focused Ultrasound International Symposium 10/9/2014
Pinnacle Biologics, A Subsidiary Of Concordia Healthcare Corp (CXR.TO), Announces European Site Initiation Of Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 10/7/2014
Acacia Pharma Touts Positive Phase 3 Data For APD421 10/7/2014
AnGes MG Inc. Starts Global Phase 3 Clinical Trials Of Collategene® For Critical Limb Ischemia 10/6/2014
Alcobra (ADHD)'s ADHD Drug Metadoxine Meets Goals In Late-Stage Study 10/6/2014
Norgine Enrolls First Patient In The Phase 3 NOCT Study To Evaluate Bowel Cleansing Efficacy Of NER1006, A Novel, Low Volume Bowel Preparation, Vs. Trisulfate 10/3/2014
Novartis AG (NVS) To Roll Out 15 Abstracts At EADV 10/1/2014
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Novartis AG (NVS) Reports Two Positive Phase 3 Trials For Arthritis Drug 9/26/2014
Bausch & Lomb Announces Successful Results From Phase 3 Study Of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% 9/26/2014
Roche (RHHBY)’s Avastin Prolongs Life In Breast Cancer Study 9/25/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014
Helsinn Announces That Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Will Be Presented At The 38th European Society For Medical Oncology (ESMO) Congress In 2014 9/25/2014
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014
Novo Nordisk A/S (NVO)'s Diabetes Drug Ryzodeg Effective In Phase 3b Study 9/18/2014
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
Early Phase 3 Data Suggest Sanofi (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
Bayer Inc. Release: Nexavar® (sorafenib tablets) Now Approved In Canada For The Treatment Of Differentiated Thyroid Cancer 7/7/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
Agreement On Phase 3 Trial Protocol Of OSE Pharma's OSE-2101 From The FDA And European Medicines Agency 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014
EULAR: Romosozumab Significantly Increases Bone Mineral Density And Bone Content Compared With Teriparatide 6/11/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014
ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen 6/9/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014